New dengue drug could cut fever time and virus levels
NCT ID NCT06006559
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 2 trial tests an experimental drug called EYU688 in 108 adults with dengue fever. Participants receive either the drug or a placebo to see if it lowers the amount of virus in the blood and shortens fever. The study is currently recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
EYU688
What this could lead to
If it works, this could lead to a new treatment that shortens dengue fever and reduces the amount of virus in the blood.
What could go wrong
This is an early Phase 2 trial with only 108 participants, so results may not apply to everyone. The drug may not work better than placebo, and side effects are still being studied.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DENGUE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Novartis Investigative Site
RECRUITINGManaus, Amazonas, 69040-000, Brazil
-
Novartis Investigative Site
RECRUITINGBrasília, Federal District, 71635-580, Brazil
-
Novartis Investigative Site
RECRUITINGRio de Janeiro, Rio de Janeiro, 21040-360, Brazil
-
Novartis Investigative Site
RECRUITINGSorocaba, São Paulo, 18040-425, Brazil
-
Novartis Investigative Site
RECRUITINGSao Jose Rio Preto, 15090 000, Brazil
-
Novartis Investigative Site
RECRUITINGBarranquilla, Atlántico, 080012, Colombia
-
Novartis Investigative Site
RECRUITINGBucaramanga, Santander Department, 681017, Colombia
-
Novartis Investigative Site
RECRUITINGCali, Valle del Cauca Department, 760032, Colombia
-
Novartis Investigative Site
RECRUITINGBelagavi, Karnataka, 590010, India
-
Novartis Investigative Site
WITHDRAWNMumbai, Maharashtra, 400008, India
-
Novartis Investigative Site
RECRUITINGPune, Maharashtra, 411013, India
-
Novartis Investigative Site
RECRUITINGJaipur, Rajasthan, 302017, India
-
Novartis Investigative Site
RECRUITINGChennai, Tamil Nadu, 600113, India
-
Novartis Investigative Site
RECRUITINGKuantan, Pahang, 25200, Malaysia
-
Novartis Investigative Site
RECRUITINGIpoh, Perak, 30450, Malaysia
-
Novartis Investigative Site
RECRUITINGSeberang Jaya, Pulau Pinang, 13700, Malaysia
-
Novartis Investigative Site
RECRUITINGMiri, Sarawak, 98000, Malaysia
-
Novartis Investigative Site
RECRUITINGKuala Selangor, 68000, Malaysia
-
Novartis Investigative Site
RECRUITINGSingapore, 169608, Singapore
-
Novartis Investigative Site
RECRUITINGSingapore, S308433, Singapore
-
Novartis Investigative Site
RECRUITINGHaiphong, 180000, Vietnam
-
Novartis Investigative Site
RECRUITINGHanoi, 100000, Vietnam
-
Novartis Investigative Site
RECRUITINGHo Chi Minh City, 700000, Vietnam